Scarica l'app Stockscreener
0.7251
2.87%
-0.0214
Dopo l'orario di chiusura:
.73
0.0049
+0.68%
Precedente Chiudi:
$0.7465
Aprire:
$0.73
Volume 24 ore:
1.35M
Relative Volume:
0.34
Capitalizzazione di mercato:
$71.05M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.41%
1M Prestazione:
-10.72%
6M Prestazione:
-86.03%
1 anno Prestazione:
-80.61%
Intervallo 1D:
$0.7171
$0.7451
Intervallo di 1 settimana:
$0.7106
$0.80
Portata 52W:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.7251 | 73.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
How aTyr Pharma Inc. stock benefits from tech adoptionMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Will aTyr Pharma Inc. stock outperform growth indexesTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Can aTyr Pharma Inc. (471A) stock sustain breakout momentumDay Trade & Safe Capital Allocation Plans - ulpravda.ru
Aug EndMonth: Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
How strong is aTyr Pharma Inc. stock revenue growthPortfolio Return Report & Low Risk Investment Opportunities - ulpravda.ru
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a 483% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Will aTyr Pharma Inc. stock attract ESG investorsStock Watchlist Updates & Exceptional Trading Strategies - ulpravda.ru
aTyr Pharma, Inc.Common Stock (NQ: ATYR - FinancialContent
Will aTyr Pharma Inc. (471A) stock beat Nasdaq index returns2026 world cup usa national team quarterfinals playmakers high defensive line expert forecast preview - Улправда
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR)Join by December 8, 2025Contact Levi & Korsinsky - The National Law Review
Is aTyr Pharma Inc. stock affected by interest rate hikesJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - Улправда
How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Buyback Activity & Fast Momentum Stock Entry Tips - Улправда
ATyr Pharma, Inc.(NasdaqCM:ATYR) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will aTyr Pharma Inc. stock remain a Wall Street favorite2025 Top Gainers & Technical Confirmation Alerts - Улправда
Winners Losers: Will aTyr Pharma Inc. stock remain a Wall Street favoriteWeekly Investment Recap & Accurate Entry/Exit Alerts - Улправда
Why analysts raise outlook for aTyr Pharma Inc. (471A) stockExit Point & AI Forecast for Swing Trade Picks - DonanımHaber
Aug Fed Impact: How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - marketscreener.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Hold” by Brokerages - Defense World
Healthy Upside Potential: Atyr Pharma Inc (ATYR) - Setenews
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Morningstar
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Le - GuruFocus
Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - Louisiana First News
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - galvnews.com
ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc - GuruFocus
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - marketscreener.com
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securi - GuruFocus
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - TMX Newsfile
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, - GlobeNewswire
aTyr Pharma Receives Nasdaq Deficiency Notice - TipRanks
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class ActionATYR - cnhinews.com
ATyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Prime Publishers, Inc.
SueWallSt Podcast Series Launches With Focus on aTyr Pharma, Inc. (ATYR) Fraud Allegations - ACCESS Newswire
ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - marketscreener.com
Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):